Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M, Laginestra MA, Durante G, Mancarella C, Landuzzi L, Parra A, Ruzzi F, Toracchio L, De Feo A, Giusti V, Pasello M, Righi A, Lollini PL, Palmerini E, Donati DM, Manara MC, Scotlandi K. Carrabotta M, et al. Among authors: ruzzi f. Cancer Res. 2022 Feb 15;82(4):708-720. doi: 10.1158/0008-5472.CAN-21-1222. Cancer Res. 2022. PMID: 34903601 Free PMC article.
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, Pasello M, Parra A, Carrabotta M, Ferracin M, Palladini A, Ianzano ML, Giusti V, Ruzzi F, Magnani M, Donati DM, Picci P, Lollini PL, Scotlandi K. Nanni P, et al. Among authors: ruzzi f. Sci Rep. 2019 Aug 21;9(1):12174. doi: 10.1038/s41598-019-48634-y. Sci Rep. 2019. PMID: 31434953 Free PMC article.
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.
Landuzzi L, Palladini A, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, Ruzzi F, Ianzano ML, Scalambra L, Laranga R, Balboni T, Arigoni M, Olivero M, Calogero RA, De Giovanni C, Dall'Ora M, Di Oto E, Santini D, Foschini MP, Cucchi MC, Zanotti S, Taffurelli M, Nanni P, Lollini PL. Landuzzi L, et al. Among authors: ruzzi f. Sci Rep. 2021 Jan 15;11(1):1563. doi: 10.1038/s41598-021-81085-y. Sci Rep. 2021. PMID: 33452364 Free PMC article.
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.
De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL. De Giovanni C, et al. Among authors: ruzzi f. Cancers (Basel). 2019 Apr 11;11(4):517. doi: 10.3390/cancers11040517. Cancers (Basel). 2019. PMID: 30979001 Free PMC article.
IFN-γ and CD38 in Hyperprogressive Cancer Development.
Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. Angelicola S, et al. Among authors: ruzzi f. Cancers (Basel). 2021 Jan 15;13(2):309. doi: 10.3390/cancers13020309. Cancers (Basel). 2021. PMID: 33467713 Free PMC article. Review.
IL-1 Family Members in Bone Sarcomas.
Landuzzi L, Ruzzi F, Pellegrini E, Lollini PL, Scotlandi K, Manara MC. Landuzzi L, et al. Among authors: ruzzi f. Cells. 2024 Jan 25;13(3):233. doi: 10.3390/cells13030233. Cells. 2024. PMID: 38334625 Free PMC article. Review.
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.
Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, Pittino OM, Nanni P, Lollini PL. Ruzzi F, et al. Int J Mol Sci. 2023 Aug 19;24(16):12963. doi: 10.3390/ijms241612963. Int J Mol Sci. 2023. PMID: 37629147 Free PMC article. Review.
16 results